Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes Robert L. Kormos, MD, Jeffrey J. Teuteberg, MD, Francis D. Pagani, MD, Stuart D. Russell, MD, Ranjit John, MD, Leslie W. Miller, MD, Todd Massey, MD, Carmelo A. Milano, MD, Nader Moazami, MD, Kartik S. Sundareswaran, PhD, David J. Farrar, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 139, Issue 5, Pages 1316-1324 (May 2010) DOI: 10.1016/j.jtcvs.2009.11.020 Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions
Figure 1 Kaplan–Meier survival for patients with and without early RVF receiving the HeartMate II LVAD, which includes the need for RVADs or extended inotropic support for more than 14 days. The Journal of Thoracic and Cardiovascular Surgery 2010 139, 1316-1324DOI: (10.1016/j.jtcvs.2009.11.020) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions
Figure 2 Relative risk ratios of univariate and multivariate predictors of RVF during LVAD support. The Journal of Thoracic and Cardiovascular Surgery 2010 139, 1316-1324DOI: (10.1016/j.jtcvs.2009.11.020) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions